What’s the current market cap for Cencora stock?

Cencora (COR) has a market cap of $56bn as of June 29, 2026.

What is the P/E ratio for Cencora stock?

The price to earnings (P/E) ratio for Cencora (COR) stock is 21.92 as of June 29, 2026.

Does Cencora stock pay dividends?

Yes, the Cencora (COR) stock pays dividends to shareholders. As of June 29, 2026, the dividend rate is $2.35 and the yield is 0.84%. Cencora has a payout ratio of 18.01% on a trailing twelve-month basis.

When is the next Cencora dividend payment date?

The next Cencora (COR) dividend payment date is unconfirmed.

What is the beta indicator for Cencora?

Cencora (COR) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Cencora stock | $COR Share Price

About Cencora

Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Ticker

$COR

Sector

Health

Primary listing

NYSE

Employees

49,000

Headquarters

Conshohocken, United States

Website

www.cencora.com

Cencora Metrics

BasicAdvanced

$56bn

21.92

$13.05

0.64

$2.35

0.84%

What the Analysts think about Cencora

Analyst ratings (Buy, Hold, Sell) for Cencora stock.

Bulls say / Bears say

Cencora will merge its MWI Animal Health unit with Covetrus in a $3.5 billion deal, creating a comprehensive animal-health distribution and technology platform and securing $1.25 billion in cash proceeds, $800 million in preferred equity, and a 34.3% equity stake in the combined company. (Reuters)

On May 21, Cencora raised the lower end of its fiscal 2026 earnings per share guidance and approved a new $2 billion share buyback plan, underscoring strong free cash flow and a shareholder-friendly capital allocation strategy. (Reuters)

In Q2 FY2026, segment operating income increased 13.7% to $175.8 million, driven by higher operating income in the European distribution business and global specialty logistics, reflecting progress on margin expansion initiatives. (Reuters)

After missing second-quarter results, Cencora cut its full-year revenue growth forecast to 4%–6% from 7%–9%, sending shares down 18% as it grapples with slower organic growth in its core U.S. operations. (Reuters)

Total Q2 revenue of $78.4 billion fell short of the $81.09 billion consensus estimate, underscoring persistent pricing pressure from manufacturer cuts and shifts in customer purchasing patterns. (Reuters)

Growth in the U.S. Healthcare Solutions segment slowed to 2.9% year-over-year in Q2, below analysts’ expectations of roughly 4.0%, reflecting headwinds from big pharmacy customer mix shifts and branded drug price reductions. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.

Cencora Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Cencora Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Cencora News

AllArticlesVideos

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Cencora

Ticker

Primary listing

Employees

Cencora Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Cencora

Analyst Ratings

Bulls say / Bears say

Cencora Financial Performance

Income Statement

Cencora Earnings Performance

Earnings per share (EPS)

Cencora News

Cencora Announces Samantha Hammock as Chief Human Resources Officer

Cencora revises forecast for 2026, approves $2 billion share buyback

Cencora Announces Updated Fiscal Year 2026 Financial Outlook

Buy $COR

Lightyear

Legal

Work with us

Bulls say / Bears say

Cencora/$COR

About Cencora

Ticker

Primary listing

Employees

Cencora Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Cencora

Analyst Ratings

Bulls say / Bears say

Cencora Financial Performance

Income Statement

Cencora Earnings Performance

Earnings per share (EPS)

Cencora News

Cencora Announces Samantha Hammock as Chief Human Resources Officer

Cencora revises forecast for 2026, approves $2 billion share buyback

Cencora Announces Updated Fiscal Year 2026 Financial Outlook

What’s the current market cap for Cencora stock?

What is the P/E ratio for Cencora stock?

Does Cencora stock pay dividends?

When is the next Cencora dividend payment date?

What is the beta indicator for Cencora?

Bulls say / Bears say